New drug combo aims to shrink kidney tumors before surgery

NCT ID NCT06794229

Recruiting now Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This study tests whether taking zanzalintinib (a pill) plus nivolumab (an IV drug) for 12 weeks can shrink advanced kidney tumors enough to allow surgery. About 69 adults with locally advanced or inoperable clear cell renal cell carcinoma will take part. After 12 weeks, doctors will check if surgery is now possible; if not, treatment may continue for up to 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RENAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

Contact Email: •••••@•••••

Contact

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED RENAL CELL CARCINOMA